Show simple item record

dc.contributor.authorBulduk, Bengisu K.
dc.contributor.authorTortajada, Juan
dc.contributor.authorValiente Pallejà, Alba
dc.contributor.authorCallado Hernando, Luis Felipe ORCID
dc.contributor.authorTorrell, Helena
dc.contributor.authorVilella, Elisabet
dc.contributor.authorMeana Martínez, José Javier ORCID
dc.contributor.authorMuntané, Gerard
dc.contributor.authorMartorell, Lourdes
dc.date.accessioned2024-08-07T10:25:58Z
dc.date.available2024-08-07T10:25:58Z
dc.date.issued2024-07
dc.identifier.citationPsychiatry Research 337 : (2024) // Article ID 115928es_ES
dc.identifier.issn1872-7123
dc.identifier.urihttp://hdl.handle.net/10810/69200
dc.description.abstractPrevious studies have shown mitochondrial dysfunction in schizophrenia (SZ) patients, which may be caused by mitochondrial DNA (mtDNA) alterations. However, there are few studies in SZ that have analyzed mtDNA in brain samples by next-generation sequencing (NGS). To address this gap, we used mtDNA-targeted NGS and qPCR to characterize mtDNA alterations in brain samples from patients with SZ (n = 40) and healthy controls (HC) (n = 40). 35 % of SZ patients showed mtDNA alterations, a significantly higher prevalence compared to 10 % of HC. Specifically, SZ patients had a significantly higher frequency of deletions (35 vs. 5 in HC), with a mean number of deletions of 3.8 in SZ vs. 1.0 in HC. Likely pathogenic missense variants were also significantly more frequent in patients with SZ than in HC (10 vs. three HC), encompassing 14 variants in patients and three in HC. The pathogenic tRNA variant m.3243A>G was identified in one SZ patient with a high heteroplasmy level of 32.2 %. While no significant differences in mtDNA copy number (mtDNA-CN) were observed between SZ and HC, antipsychotic users had significantly higher mtDNA-CN than non-users. These findings suggest a potential role for mtDNA alterations in the pathophysiology of SZ that require further validation and functional studies.es_ES
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III grant numbers PI18/00514 and PI21/01812, the Basque Government (IT-1512/22 and 2021111018), the Catalan Agency for Research and Universities (AGAUR) 2017SGR-00444 and 2021SGR-01065, the IISPV-Cerca program of the Generalitat de Catalunya, and co-funded by the European Union. Alba Valiente-Pallejà received a Talent-URV-Dipta grant from the Diputació de Tarragona. Bengisu K. Bulduk had a scholarship (FIDGR-2020) and Juan Tortajada had an industrial doctorate (DI21–85), both from the Generalitat de Catalunya.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectmitochondrial DNAes_ES
dc.subjectschizophreniaes_ES
dc.subjectpostmortem braines_ES
dc.subjectnext-generation sequencinges_ES
dc.titleHigh number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controlses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0165178124002130es_ES
dc.identifier.doi10.1016/j.psychres.2024.115928
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license.
Except where otherwise noted, this item's license is described as © 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license.